Brief: Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
23/04/2025 22:00
April 23 (Reuters) - Verastem Inc VSTM.O: VERASTEM ONCOLOGY ANNOUNCES U.S. IND CLEARANCE OF VERSUS-7375, ORAL KRAS G12D (ON/OFF) INHIBITOR, ENABLING PHASE 1/2A TRIAL IN ADVANCED SOLID TUMORS VERASTEM INC - PHASE 1/2A TRIAL IN U.S. TO START MID-2025 Source text: ID:nBw4MkxWYa Further company coverage: VSTM.O ((Reuters.Briefs@thomsonreuters.com))